TY - JOUR
T1 - Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas
T2 - An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation
AU - Kharfan-Dabaja, Mohamed A.
AU - Kumar, Ambuj
AU - Ayala, Ernesto
AU - Hamadani, Mehdi
AU - Reimer, Peter
AU - Gisselbrecht, Christian
AU - d'Amore, Francesco
AU - Jantunen, Esa
AU - Ishida, Takashi
AU - Bazarbachi, Ali
AU - Foss, Francine
AU - Advani, Ranjana
AU - Fenske, Timothy S.
AU - Lazarus, Hillard M.
AU - Friedberg, Jonathan W.
AU - Aljurf, Mahmoud
AU - Sokol, Lubomir
AU - Tobinai, Kensei
AU - Tse, Eric
AU - Burns, Linda J.
AU - Chavez, Julio C.
AU - Reddy, Nishitha M.
AU - Suzuki, Ritsuro
AU - Ahmed, Sairah
AU - Nademanee, Auayporn
AU - Mohty, Mohamad
AU - Gopal, Ajay K.
AU - Fanale, Michelle A.
AU - Pro, Barbara
AU - Moskowitz, Alison J.
AU - Sureda, Anna
AU - Perales, Miguel Angel
AU - Carpenter, Paul A.
AU - Savani, Bipin N.
N1 - Funding Information:
Conflict of interest statement: M.A.K.-D.: speaker's bureau for Seattle Genetics. E.A.: advisory board for Seattle Genetics. F.d.A., advisory board forTakeda, Servier, Nordic Nanovector; speaker's honoraria from Servier and Takeda; research support from Roche, Sanofi, and Takeda. T.I.: research funding from Kyowa Hakko Kirin Co., Ltd., Bayer Pharma AG, and J-Pharma Co., Ltd; honoraria from Kyowa Hakko Kirin Co., Ltd. R.A: Institute research funding from Merck, Janssen, BMS, Seattle Genetics, Celgene, Kura Pharmacyclics, Forty seven, Roche/Genentech, Regeneron, Agensys, Millennium; advisory board honoraria from BMS, Sutro, Bayer, Roche/Genetech, Pharmacyclics, Astra Zeneca, cell medica. T.S.F: consultant for Celgene, Seattle Genetics, Pharmacyclics and Sanofi; speaker for Celgene and Sanofi. H.M.L: promotional speaker for Seattle Genetics. L.S: speaker for spectrum pharmaceuticals, advisory boards for Mallinckrodt Pharmaceuticals and Seattle Genetics. K.T: research funding from Mundipharma K.K., Kyowa Hakko Kirin, Eisai, Takeda; Honoraria from Eisai, Takeda, Mundipharma K.K., Huya Bioscience International, Kyowa Hakko Kirin, Celgene. N.M.R: AbbVie, BMS, Celgene, Gilead. A.K.G: funding from Merck, Janssen, Teva, BMS, Pfizer, Seattle Genetics, Effector, Gilead, Takeda; consultancy for Brim biotech, Seattle Genetics, Janssen, Gilead, Aptevo. M.A.F: research funding from Celgene, Takeda, Seattle Genetics, BMS, Merck; honoraria from BMS, Seattle Genetics, Merck; advisory board for BMS and Merck. M.A.P: advisory board for Seattle Genetics, Merck, and Incyte, research support from Incyte. The following authors declare no conflicts of interest: A.K., M.H., P.R., C.G., E.J., A.B., F.F., J.W.F., M.A., E.T., L.J.B., J.C.C., S.A., A.N., M.M., R.S., B.P., A.M., A.S., P.A.C., and B.N.S.
Publisher Copyright:
© 2017 The American Society for Blood and Marrow Transplantation
PY - 2017/11
Y1 - 2017/11
N2 - Recognizing the significant biological and clinical heterogeneity of mature T cell and natural killer (NK)/T cell lymphomas, the American Society for Blood and Marrow Transplantation invited experts to develop clinical practice recommendations related to the role of autologous hematopoietic cell transplantation (auto-HCT) and allogeneic HCT (allo-HCT) for specific histological subtypes. We used the GRADE methodology to aid in moving from evidence to decision making and ultimately to generating final recommendations. Auto-HCT in front-line consolidation is recommended in peripheral T cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T cell lymphoma (AITL), anaplastic large cell lymphoma–anaplastic lymphoma kinase (ALCL-ALK)-negative, NK/T cell (disseminated), enteropathy-associated T cell lymphoma (EATL), and hepatosplenic lymphomas. Auto-HCT in relapsed-sensitive disease is recommended for NK/T cell (localized and disseminated), EATL, subcutaneous panniculitis-like T cell, and ALCL-ALK–positive lymphomas. Auto-HCT is also recommended for PTCL-NOS, AITL, and ALCL-ALK–negative lymphomas if not performed as front-line therapy. Auto-HCT in refractory (primary or relapsed) disease is not recommended for any of the histological subtypes discussed. Allo-HCT in front-line consolidation is recommended for NK/T cell (disseminated), adult T cell leukemia/lymphoma (ATLL; acute and lymphoma type), and hepatosplenic lymphomas. Allo-HCT for relapsed-sensitive disease is recommended for PTCL-NOS, AITL, ALCL-ALK–negative, ALCL-ALK–positive, NK/T cell (localized and disseminated), ATLL (acute, lymphoma type, smoldering/chronic), mycosis fungoides/Sezary syndrome (advanced stage IIB-IVB or tumor stage/extracutaneous), EATL, subcutaneous panniculitis-like T cell, and hepatosplenic lymphoma. Allo-HCT in refractory (primary or relapsed refractory) disease is recommended for any aforementioned histological subtypes. Emerging novel therapies will likely be incorporated into the pretransplantation, peritransplantation, and post-transplantation algorithms (auto-HCT or allo-HCT) with the goals of optimizing efficacy and improving outcomes. We acknowledge that there are unique clinical scenarios not covered by these recommendations that may require individualized decisions.
AB - Recognizing the significant biological and clinical heterogeneity of mature T cell and natural killer (NK)/T cell lymphomas, the American Society for Blood and Marrow Transplantation invited experts to develop clinical practice recommendations related to the role of autologous hematopoietic cell transplantation (auto-HCT) and allogeneic HCT (allo-HCT) for specific histological subtypes. We used the GRADE methodology to aid in moving from evidence to decision making and ultimately to generating final recommendations. Auto-HCT in front-line consolidation is recommended in peripheral T cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T cell lymphoma (AITL), anaplastic large cell lymphoma–anaplastic lymphoma kinase (ALCL-ALK)-negative, NK/T cell (disseminated), enteropathy-associated T cell lymphoma (EATL), and hepatosplenic lymphomas. Auto-HCT in relapsed-sensitive disease is recommended for NK/T cell (localized and disseminated), EATL, subcutaneous panniculitis-like T cell, and ALCL-ALK–positive lymphomas. Auto-HCT is also recommended for PTCL-NOS, AITL, and ALCL-ALK–negative lymphomas if not performed as front-line therapy. Auto-HCT in refractory (primary or relapsed) disease is not recommended for any of the histological subtypes discussed. Allo-HCT in front-line consolidation is recommended for NK/T cell (disseminated), adult T cell leukemia/lymphoma (ATLL; acute and lymphoma type), and hepatosplenic lymphomas. Allo-HCT for relapsed-sensitive disease is recommended for PTCL-NOS, AITL, ALCL-ALK–negative, ALCL-ALK–positive, NK/T cell (localized and disseminated), ATLL (acute, lymphoma type, smoldering/chronic), mycosis fungoides/Sezary syndrome (advanced stage IIB-IVB or tumor stage/extracutaneous), EATL, subcutaneous panniculitis-like T cell, and hepatosplenic lymphoma. Allo-HCT in refractory (primary or relapsed refractory) disease is recommended for any aforementioned histological subtypes. Emerging novel therapies will likely be incorporated into the pretransplantation, peritransplantation, and post-transplantation algorithms (auto-HCT or allo-HCT) with the goals of optimizing efficacy and improving outcomes. We acknowledge that there are unique clinical scenarios not covered by these recommendations that may require individualized decisions.
KW - Allogeneic hematopoietic cell transplantation
KW - Autologous hematopoietic cell transplantation
KW - NK/T cell lymphomas
KW - T cell lymphomas
UR - http://www.scopus.com/inward/record.url?scp=85030979951&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030979951&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2017.07.027
DO - 10.1016/j.bbmt.2017.07.027
M3 - Article
C2 - 28797780
AN - SCOPUS:85030979951
SN - 1083-8791
VL - 23
SP - 1826
EP - 1838
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 11
ER -